Literature DB >> 3721067

Biosynthesis and processing of the human insulin receptor.

J Forsayeth, B Maddux, I D Goldfine.   

Abstract

We investigated the biosynthesis of the human insulin receptor in IM-9 lymphocytes and HEP-G2 hepatoma cells. Cells were first pulse labeled for 15 min with [35S]methionine and then chased for up to 4 h. At each time, the cells were solubilized in 1% Triton X-100; the insulin receptor was immunoprecipitated and then analyzed with sodium dodecyl sulfate-polyacrylamide gel electrophoresis (6%) and fluorography. At 15 min, a major precursor protein of 190,000 Mr was precipitated. During the chase period, two smaller proteins became apparent, which evolved into two major species of 130,000 and 95,000 Mr, the mature alpha- and beta-subunits, respectively. When IM-9 cells were trypsinized after pulse chase, the alpha- and beta-subunits were completely digested, whereas the 190,000-Mr precursor was unaffected. 125I-surface labeling of cells, followed by immunoprecipitation, revealed the presence of only the alpha- and beta-subunits, indicating that only these two species were on the cell surface. To study this biosynthetic pathway, several inhibitors were used (tunicamycin, monensin, and swainsonine). These inhibitors revealed the following. The receptor is first synthesized as a 170,000-Mr protein that is cotranslationally N-glycosylated to yield a high-mannose 190,000-Mr precursor. This precursor is rapidly transported from the endoplasmic reticulum to the Golgi apparatus where it is cleaved into two subunits of 120,000 Mr (alpha) and 90,000 Mr (beta). These subunits then increase in molecular weight by processing of the high-mannose oligosaccharides to the low-mannose complex type. The two subunits then migrate to the cell surface where they function to transmit the insulin signal.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3721067     DOI: 10.2337/diab.35.7.837

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  8 in total

1.  Transdominant inhibition of tyrosine kinase activity in mutant insulin/insulin-like growth factor I hybrid receptors.

Authors:  J L Treadway; B D Morrison; M A Soos; K Siddle; J Olefsky; A Ullrich; D A McClain; J E Pessin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

2.  Immunological demonstration of the accumulation of insulin, but not insulin receptors, in nuclei of insulin-treated cells.

Authors:  A P Soler; K A Thompson; R M Smith; L Jarett
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

3.  Muscle cell differentiation is associated with increased insulin receptor biosynthesis and messenger RNA levels.

Authors:  A Brunetti; B A Maddux; K Y Wong; I D Goldfine
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

4.  Elevated insulin receptor content in human breast cancer.

Authors:  V Papa; V Pezzino; A Costantino; A Belfiore; D Giuffrida; L Frittitta; G B Vannelli; R Brand; I D Goldfine; R Vigneri
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

5.  Insulin receptor content in tissues of normal and diabetic rats measured by radioimmunoassay.

Authors:  V Pezzino; A Costantino; P Russo; D Gullo; V Papa
Journal:  J Endocrinol Invest       Date:  1996-10       Impact factor: 4.256

6.  Regulation of insulin-like growth factor (IGF) I receptor expression during muscle cell differentiation. Potential autocrine role of IGF-II.

Authors:  S M Rosenthal; A Brunetti; E J Brown; P W Mamula; I D Goldfine
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

7.  High-affinity insulin binding to an atypical insulin-like growth factor-I receptor in human breast cancer cells.

Authors:  G Milazzo; C C Yip; B A Maddux; R Vigneri; I D Goldfine
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

8.  Intracellular and surface distribution of a membrane protein (CD8) derived from a single nucleus in multinucleated myotubes.

Authors:  E Ralston; Z W Hall
Journal:  J Cell Biol       Date:  1989-11       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.